Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.
about
Pharmacogenetics and anaesthesia: the value of genetic profilingDosing Recommendations for Concomitant Medications During 3D Anti-HCV TherapyEvaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affectPharmacogenomic considerations in opioid analgesia.Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4.Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.Pharmacogenetics of analgesic drugsOpioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk managementImpact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.Oxycodone for the treatment of postoperative pain.Opioid genetics: the key to personalized pain control?Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.Do children have the same vulnerability to metabolic drug–drug interactions as adults? A critical analysis of the literature.Use of oxycodone in pain management.Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model.Observations of urinary oxycodone and metabolite distributions in pain patients.Rat brain CYP2D activity alters in vivo central oxycodone metabolism, levels and resulting analgesia.Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration.Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain.Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer-Which Factors Matter?
P2860
Q26859221-32A2E1EC-5A2F-4E28-AEA1-D2955BCEFECFQ28080752-D081310E-0CBD-4716-837A-46693F280CB8Q33838839-D9B636D2-C3F1-4CAE-A37E-777575877DCDQ34316700-57518CBD-EC1C-445A-9606-F4C2732DD7B7Q34737242-94CD8F72-EBDC-48DB-88F7-90FE60263E3EQ35644151-304989F3-DB17-41F8-AF0F-467615951C02Q36110592-BCCF56F3-0AE5-43C4-9FAD-A344F834F856Q36392325-EB33A17D-CC5F-41A6-9BF7-259F3277731FQ37207816-7E7F28C7-9923-447A-914A-A536E631263EQ38004077-7B67D7D8-015A-47F6-A7DB-9F45D459835AQ38025200-02E71B34-815E-40BE-AEB8-862711FF2BCAQ38100710-058922DB-F67E-423D-913A-9065B20B71A5Q38110809-5C1C08A1-B9C3-4B8D-86E7-01B52CAE341FQ39533902-7D80AE7C-9BEC-4891-963F-6A8D844B135DQ41678423-3E9B0C40-426D-4D79-B684-E0AFA005D566Q46121183-E4F1F8BF-45E7-46DB-B730-16752E5CBA09Q47561935-C3262A25-A1C2-42CC-8D2F-024E19ACB970Q48127325-47090148-59A4-47C0-BC76-9FED65428B9FQ48721652-4E36CE95-76A5-4AAD-9624-332947166DE5Q50568090-6D83885B-8C0E-45EC-A9B0-E2CE94BB6471
P2860
Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Exposure to oral oxycodone is ...... by inhibition of CYP2D6 alone.
@ast
Exposure to oral oxycodone is ...... by inhibition of CYP2D6 alone.
@en
Exposure to oral oxycodone is ...... by inhibition of CYP2D6 alone.
@nl
type
label
Exposure to oral oxycodone is ...... by inhibition of CYP2D6 alone.
@ast
Exposure to oral oxycodone is ...... by inhibition of CYP2D6 alone.
@en
Exposure to oral oxycodone is ...... by inhibition of CYP2D6 alone.
@nl
prefLabel
Exposure to oral oxycodone is ...... by inhibition of CYP2D6 alone.
@ast
Exposure to oral oxycodone is ...... by inhibition of CYP2D6 alone.
@en
Exposure to oral oxycodone is ...... by inhibition of CYP2D6 alone.
@nl
P2093
P2860
P1476
Exposure to oral oxycodone is ...... by inhibition of CYP2D6 alone.
@en
P2093
Juha Grönlund
Kari Laine
Klaus T Olkkola
Nora M Hagelberg
Teijo I Saari
P2860
P356
10.1111/J.1365-2125.2010.03653.X
P407
P577
2010-07-01T00:00:00Z